Allostatic load in psychiatry: a systematic review and meta-analysis.

StressFeb 21, 2026 (epub)
Clinical ResearchPsychiatry

Sabine Finlay, Riana Marie, Donna Rudd et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined associations between allostatic load (AL), a measure of multisystem physiological dysregulation, and psychiatric disorders. Twenty-eight studies were included in the review, with sixteen contributing to meta-analysis. AL was higher in people with psychiatric disorders than in healthy controls overall. The clearest pooled difference was for schizophrenia and first-episode psychosis (SMD: 0.97; 95% CI: 0.76, 1.18; p < .0001), whereas major depressive disorder showed no significant difference from controls (SMD: 0.07; 95% CI: -0.23; 0.37; p = 0.67).

Key findings

  • Across included studies, people with psychiatric disorders demonstrated elevated allostatic load compared with healthy controls.
  • For schizophrenia and first-episode psychosis, pooled allostatic load was higher than in healthy controls (SMD: 0.97; 95% CI: 0.76, 1.18; p < .0001).
  • For major depressive disorder, the meta-analysis found no significant allostatic-load difference from healthy controls (SMD: 0.07; 95% CI: -0.23; 0.37; p = 0.67).

Why it matters

Allostatic load may help characterise how psychiatric disorders relate to dysregulation across multiple physiological systems, rather than focusing on a single biomarker. The differing pooled results across diagnostic groups also caution against assuming that this pattern applies uniformly. Further work could clarify whether AL assessment helps identify systemic comorbidity or informs understanding of illness processes.

What to keep in mind

The review included 28 studies, but only 16 were eligible for meta-analysis; the abstract does not report further limitations.

Source

Published in Stress. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.